CDw17 Antibody / Lactosylceramide / LaCer [clone HO18.3G-6.F5] (V3087)

Catalog No.	Formulation	Size
V3087-100UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	100 ug
V3087-20UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	20 ug
V3087SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug

Bulk quote request

Availability	1-3 business days
Species Reactivity	Human
Format	Purified
Clonality	Monoclonal (mouse origin)
Isotype	Mouse IgM, kappa
Clone Name	HO18.3G-6.F5
Purity	PEG precipitation
UniProt	Not known
Localization	Cell surface
Applications	Flow Cytometry : 1-2ug/10^6 cells Immunofluorescence : 1-2ug/ml
Limitations	This CDw17 antibody is available for research use only.

Description

CD17 is an intermediate glycosphingolipid from the metabolism of higher gangliosides that localizes to sphingolipid-sterol

rafts. CD17 is detectable in monocytes, granulocytes, basophils, platelets, a subset of peripheral B cells (CD19+) and tonsil dendritic cells. It is rapidly down regulated on activated granulocytes and is upregulated on IL-2 activated T lymphocytes. CD17 binds to bacteria and may function in phagocytosis. VEGF-treated endothelial cells can produce CD17, which can then mediate signaling toward PECAM-1 expression and angiogenesis. TNFa-induced astrogliosis (astrocyte proliferation and glial fibrillary acidic protein (GFAP) upregulation) in response to neuro-inflammation (i.e. spinal cord injury) causes an increase in intracellular levels of CD17. Aberrant levels of glycosphingolipids are a feature of cancer cells and may influence integrin clustering and internalization.

Application Notes

Optimal dilution of the CDw17 antibody should be determined by the researcher.

Immunogen

Beta-2 Microglobulin associated proteins from a detergent lysate of human PBLs were used as the immunogen for the CDw17 antibody.

Storage

Store the CDw17 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).